Baird analyst Eric Coldwell raised the firm’s price target on Cardinal Health to $133 from $128 and keeps an Outperform rating on the shares. The firm said results were strong and noted the shares trade at a discount to peers even as core pharma remains very strong, its recovery including Medical is intact, and its exceptional BS/CF are driving further upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CAH:
- Cardinal Health Executives to Discuss Quarterly Results and Outlook
- Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook
- Notable companies reporting before tomorrow’s open
- M & A News: Cardinal Health (NYSE:CAH) Jumps on $1.2B Acquisition of Specialty Networks
- Cardinal Health to acquire Specialty Networks for $1.2B in cash
